Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

oxaliplatin / Generic mfg.

NCT05124002: Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Recruiting

RoW

Recombinant Human Adenovirus Type 5, H101, HAIC of FOLFOX, FOLFOX

Beijing Tsinghua Chang Gung Hospital

Cholangiocarcinoma, Intrahepatic

04/26

ChiCTR2100045251: Surufatinib plus gemcitabine and oxaliplatin (GEMOX) in patients with unresectable or metastatic biliary tract cancer (BTC): a single-arm, open-label, multi-center trial

Recruiting

Sofantinib combined with gemcitabine, oxaliplatin

The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, Company

biliary tract cancers

NCT06417606: Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Not yet recruiting

RoW

Lenvatinib, Adebrelimab, GEMOX（Gemcitabine and oxaliplatin）

Zhiyong Huang

Intrahepatic Cholangiocarcinoma

04/25

05/25

NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting

392

RoW

TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Biliary Cancer

03/22

02/23

KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Recruiting

480

RoW

KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator

3D Medicines (Sichuan) Co., Ltd.

Biliary Tract Neoplasms

07/24

NCT04961970: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Recruiting

188

RoW

oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin

Shi Ming

Intrahepatic Cholangiocarcinoma

07/25

TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting

140

Europe, Japan, US, RoW

Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen

AstraZeneca

Biliary Tract Cancer

09/25

03/26

NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Not yet recruiting

480

RoW

Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin

Shanghai Junshi Bioscience Co., Ltd.

Intrahepatic Cholangiocarcinoma

05/27

NCT04060472: Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

Not yet recruiting

2/3

albumin-bound paclitaxel + oxaliplatin

Dong Wang

Advanced Hepatobiliary and Malignant Tumors

04/21

10/23

NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting

2/3

178

RoW

Neoadjuvant treatment

Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital

Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy

12/22

12/24

2017-002330-23: EVALUATION OF THE EFFICACY AND TOLERANCE OF A CHEMOTHERAPY BY GEMCITABINE AND OXALIPLATIN ADMINISTERED IN THE LIVER, BY THE HEPATIC ARTERY, ON A CHOLANGIOCARCINOME EVALUATION DE L'EFFICACITE ET DE LA TOLERANCE D'UNE CHIMIOTHERAPIE PAR GEMCITABINE ET OXALIPLATINE ADMINISTREE DANS LE FOIE, PAR L'ARTERE HEPATIQUE, SUR UN CHOLANGIOCARCINOME

Ongoing

Europe

Solution for injection

University hospital of Montpellier, University hospital of Montpellier

The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months L’association de la gemcitabine et de l’oxaliplatine par voie intra-artérielle comme traitement de seconde ligne peut fortement améliorer le Trouble de Réponse Objective (TRO) à 4 mois., The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months L’association de la gemcitabine et de l’oxaliplatine par voie intra-artérielle comme traitement de seconde ligne peut fortement améliorer le Trouble de Réponse Objective (TRO) à 4 mois., Diseases [C] - Cancer [C04]

zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Active, not recruiting

RoW

combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)

Shanghai Zhongshan Hospital

Cholangiocarcinoma, Intrahepatic

01/20

11/21

NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting

128

RoW

neoadjuvant treatment

Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital

Cholangiocarcinoma, Intrahepatic

08/21

08/23

zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Active, not recruiting

RoW

Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib

Shanghai Zhongshan Hospital

Cholangiocarcinoma, Intrahepatic

09/21

12/21

NCT04769908: Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Recruiting

RoW

Systemic Chemotherapy, Lenvatinib, Sintilimab

Sun Yat-sen University

ICC

12/21

NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma

Recruiting

RoW

Gemox combimed PD1 antibody

Shanghai Zhongshan Hospital

Intrahepatic Cholangiocarcinoma

12/21

12/22

NCT05036798: Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Active, not recruiting

RoW

Tislelizumab, Lenvatinib, Gemox

Tianjin Medical University Cancer Institute and Hospital

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

07/22

12/23

QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC+TAE, Tislelizumab, Surufatinib

Qilu Hospital of Shandong University, BeiGene

Intrahepatic Cholangiocarcinoma

05/24

12/25

NCT04523402: Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Not yet recruiting

100

Neoadjuvant chemotherapy, Preoperative chemotherapy

Eastern Hepatobiliary Surgery Hospital

Intrahepatic Cholangiocarcinoma Recurrent

12/22

12/23

NCT05291052: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors

Recruiting

RoW

Tislelizumab, Lenvatinib, Oxaliplatin, Capecitabine

The First Affiliated Hospital with Nanjing Medical University

Biliary Tract Tumor

03/23

03/24

NCT04834674: DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Recruiting

RoW

DEB-TACE combined with apatinib and PD-1 antibody

Sichuan Cancer Hospital and Research Institute

Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody

04/25

04/26

NCT05290116: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC Combined with Tislelizumab and Apatinib

Yunfei Yuan

Intrahepatic Cholangiocarcinoma

05/23

09/23

GWK2023-001, NCT06335927: HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Recruiting

RoW

HAIC-GEMOX+Cadonilimab+Regorafenib

Fudan University

Intrahepatic Cholangiocarcinoma

05/25

05/26

NCT05448183: An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Recruiting

RoW

Toripalimab, Gemcitabine,Oxaliplatin

Xuhua Duan

Extrahepatic Cholangiocarcinoma

05/23

05/24

NCT04217954: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Completed

RoW

OXA, 5-FU and bevacizumab plus Toripalimab, FOLFOX

Peking University

Advanced Biliary Tract Cancer

05/23

06/23

GEMOXIA-02, NCT03364530: Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Recruiting

Europe

Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy

University Hospital, Montpellier, Federation Francophone de Cancerologie Digestive

Cholangiocarcinoma Non-resectable, Non-metastatic

06/24

06/25

KCSG-HB19-14, NCT04722133: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

Completed

RoW

HERZUMA+mFOLFOX

Yonsei University

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

06/23

NCT05348811: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Recruiting

RoW

HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab

Zhongda Hospital

Cholangiocarcinoma

06/23

07/23

NCT05620498: Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Recruiting

RoW

tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX

Tianjin Medical University Cancer Institute and Hospital

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

06/23

03/24

NCT04984980: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Active, not recruiting

RoW

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab

Fudan University

Biliary Tract Carcinoma, Initially Unresectable

07/23

NCT03603834: Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Recruiting

RoW

mFOLFOXIRI, Oxaliplatin, Irinotecan, Fluorouracil, Leucovorin

Khon Kaen University

Cholangiocarcinoma

08/23

12/23

NCT04191343: Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

Recruiting

RoW

Toripalimab injection combined with GEMOX

Zhejiang Cancer Hospital

Advanced Biliary Tract Tumors

09/23

06/24

NCT06134193: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Not yet recruiting

HAIC, Surufatinib, Tislelizumab

Wuhan Union Hospital, China

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer, Surufatinib, Angiogenesis Inhibitors, Tislelizumab, Antineoplastic Agents, Immunological, Immunotherapy

06/24

06/25

NCT04668976: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Recruiting

100

Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)

Benaroya Research Institute, Virginia Mason Hospital/Medical Center

Colorectal Cancer, Cholangiocarcinoma

12/23

12/24

NCT05024513: Biliary Drainage Plus HAIC in Locally Advanced pCCA

Recruiting

127

RoW

oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care, External biliary drainage

Peking University

Perihilar Cholangiocarcinoma

12/24

12/25

NCT05935579: Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting

RoW

Durvalumab, Lenvatinib Oral Product, Chemotherapy

Peking Union Medical College Hospital

Biliary Tract Neoplasms, Immunotherapy

12/23

12/24

NCT03406299: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Active, not recruiting

RoW

Tegafur, S-1, Leucovorin, Folinic acid, Oxaliplatin, oxalic, Gemcitabine, Gemmis, Cisplatin

National Health Research Institutes, Taiwan

Biliary Tract Neoplasms

12/23

NCT05400902: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC Combined with Tislelizumab and Apatinib

Binkui Li

Intrahepatic Cholangiocarcinoma

12/23

NCT05251662: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Recruiting

RoW

Sintilimab, IBI305, Bevacizumab Biosimilar, GEMOX

Tianjin Medical University Cancer Institute and Hospital

Intrahepatic Cholangiocarcinoma

01/24

01/25

NCT05430698: PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Recruiting

RoW

PD-1antibody plus GEMOX

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Perihilar Cholangiocarcinoma

01/24

10/25

NCT04505553: Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Active, not recruiting

Acupuncture Therapy, Acupuncture, Acupressure Therapy, acupressure, Ischemic Compression, Oral Cryotherapy, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment

University of Washington, National Cancer Institute (NCI), The Safeway Foundation

Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Rectal Carcinoma, Small Intestinal Carcinoma, Anal Carcinoma, Digestive System Carcinoma, Digestive System Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor

03/24

09/24

NCT06208462: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting

RoW

Adebrelimab, SHR-1316, Lenvatinib, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Gemcitabine, Difluorodeoxycytidine Hydrochloride, Oxaliplatin, Diaminocyclohexane Oxalatoplatinum

The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd.

Intrahepatic Cholangiocarcinoma

01/26

01/27

NCT04931420: Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Not yet recruiting

Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), thoracoscopy, thoracoscopic surgery or pleuroscopy,, Lobectomy, Consolidative Radiation, intensification therapy, postremission therapy., Ablation Treatment, Resection or Excision, Peritonectomy, Transarterial Radioembolization, TARE

University of Chicago

Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma, Gallbladder Adenocarcinoma, Liver Cancer, GI Cancer, GI Carcinoma, Lung Cancer

05/26

11/27

CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab

Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer

Cholangiocarcinoma Non-resectable

12/25

06/26

HELIX-ICC, NCT04251715: mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Active, not recruiting

Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Floxuridine, 2''-Deoxy-5-fluorouridine, 5-Fluoro-2''-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR-138720, Implanted Medical Device, IMPLANTED, Irinotecan, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment

OHSU Knight Cancer Institute, Oregon Health and Science University

Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma

06/24

11/24

NCT03693807: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Active, not recruiting

Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)

Memorial Sloan Kettering Cancer Center

Colorectal Cancer, Cholangiocarcinoma

09/24

NCT05668884: GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Recruiting

RoW

Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab

Fudan University

Biliary Tract Carcinoma

09/24

03/25

GOT, NCT05557578: Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence

Recruiting

RoW

Tislelizumab combined with GEMOX (GOT) regimen, Gemcitabine, Oxaliplatin

Zhejiang Cancer Hospital

Intrahepatic Cholangiocarcinoma

10/24

12/24

ChiCTR2200065621: A phase II study of camrelizumab plus gemcitabine and oxaliplatin followed by camrelizumab and fluzoparib or apatinib in first-line treatment for advanced or metastatic biliary tract carcinoma

Not yet recruiting

Camrelizumab(200mg,d1)+gemcitabine(800mg/m2,d1,d8)+oxaliplatin(100mg/m2,d1),Q3W,4-6 cycles, followed by camrelizumab(200mg,d1,Q3W)+fluzooparib(150mg,bid), up to 2 years ;Camrelizumab(200mg,d1)+gemcitabine(800mg/m2,d1,d8)+oxaliplatin(100mg/m2,d1),Q3W,4-6 cycles, followed by camrelizumab(200mg,d1,Q3W)+apatinib(250mg,qd), up to 2 years

Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, NA

biliary tract carcinoma

NCT05864755: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Recruiting

RoW

HAIC+Durvalumab+Tremelimumab+Bevacizumab

Tianjin Medical University Cancer Institute and Hospital

Unrescetable Hepatocellular Carcinoma

12/24

12/25

ComboMATCH Treatment Trial, NCT05564403: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A )

Recruiting

Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669

National Cancer Institute (NCI)

Recurrent Biliary Tract Carcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Distal Bile Duct Adenocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma

01/25

ChiCTR2200056808: Terelizumab combined with lenvatinib and GEMOX (gemcitabine plus oxaliplatin) as conversion therapy for unresectable extrahepatic biliary carcinoma

Not yet recruiting

Terelizumab combined with lenvatinib and GEMOX (gemcitabine + oxaliplatin)

The First Medical Center of the People's Liberation Army General Hospital; The First Medical Center of the People's Liberation Army General Hospital, Self-raised

Unresectable extrahepatic biliary carcinoma

NCT01862315: Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Active, not recruiting

Floxuridine (FUDR), dexamethasone, Gemcitabine, Oxaliplatin, MRI, Research blood draws

Memorial Sloan Kettering Cancer Center

Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma

05/25

NCT04891289: Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Recruiting

164

Gemcitabine, Oxaliplatin, Dexamethasone, Floxuridine (FUDR), Implanted Medical Device

Memorial Sloan Kettering Cancer Center

Intrahepatic Cholangiocarcinoma

05/25

ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting

Canada, US, RoW

ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine

Jazz Pharmaceuticals

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

11/25

10/26

BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting

Europe, US

LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo

Lisata Therapeutics, Inc.

Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma

12/25

HERCKER-01, NCT05985707: KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting

RoW

KN026, KN046, XELOX

Peking University Cancer Hospital & Institute

HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer

12/26

KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting

610

Europe, Canada, Japan, US, RoW

Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin

Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC

Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

02/27

NCT05286814: M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Recruiting

Floxuridine, 5-Fluorouracil, Irinotecan, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Oxaliplatin, Leucovorin, M9241, Gemcitabine, Dexamethasone

National Cancer Institute (NCI)

Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms

12/27

12/28

2013-004385-34: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Not yet recruiting

1/2

Europe

Coated tablet, Powder for solution for infusion, STIVARGA, GEMCITABINE, OXALIPLATINE

Institut régional du Cancer - Montpellier - Val d'Aurelle, Institut régional du Cancer - Montpellier - Val d'Aurelle

advanced Biliary Tract Cancer, Biliary Cancer, Diseases [C] - Cancer [C04]

NCT05116891: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed

1/2

Europe

CAN04 (nadunolimab), nadumolimab, mFOLFOX, Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin, DTX, Docetaxel, G/C, Gemcitabine and cisplatin

Cantargia AB

Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer

06/23

TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting

1/2

320

RoW

TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab

Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb

Advanced Cancer

08/24

11/24

SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting

1/2

Japan, US

tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA

Seagen Inc.

Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma

03/25

10/25

NCT06033118: Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Not yet recruiting

1/2

gemcitabine ,oxaliplatin,anlotinib,Sintilimab

Sichuan University

Combined Hepatocellular Cholangiocarcinoma

07/25

08/26

NCT05849480: A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting

1/2

oxaliplatin, capecitabine, Keytruda, CDX-1140

National Cancer Institute (NCI)

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct

06/40

06/42

PROMIFOX, NCT04729205: Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

Terminated

RoW

Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug, Folfox

Lipomedix Pharmaceuticals Inc.

Cancer, Gastro-Intestinal Intraepithelial Neoplasia

09/23

NCT04164069: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Active, not recruiting

Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment

Anne Noonan

Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma

06/23

12/23

CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

Recruiting

RoW

Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn

Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd.

Hepatocellular Carcinoma

08/24

02/25

I-FLOAT, NCT04361708: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

Recruiting

Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil

University of Chicago

Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma

06/25

05/27

ChiCTR-INR-17010977: A multicenter prospective randomized controlled trial of Folfox6 regimen in the treatment of intrahepatic cholangiocarcinoma at different stages of hepatic arterial infusion chemotherapy

Recruiting

N/A

480

The hepatic artery catheter Folfox6 chemotherapy ;Transcatheter arterial infusion chemotherapy after radical resection of ICC (Folfox 6 regimen) ;Whole-body (gemcitabine-based regimen) in the treatment of patients with unresectable middle and late ICC

The First Affiliated Hospital of Xi'an Jiaotong University,; The First Affiliated Hospital of Xi'an Jiaotong University, , National Scientific Foundation Grand

intrahepatic cholangiocarcinomas, ICC

NCT04305288: Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma

Recruiting

N/A

100

RoW

Shanghai Jiao Tong University School of Medicine

Cholangiocarcinoma of the Bile Duct

12/20

12/21

ChiCTR-IOR-16008729: A multicentre, open-label, randomised, controlled study of molecularly precision target therapy based on tumor molecular profiling with gemcitabine and oxaliplatin in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma

Recruiting

N/A

152

GEMOX ;molecularly precision target therapy with GEMOX

Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine; Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine

extrahepatic cholangiocarcinoma and gallbladder carcinoma

ChiCTR1900021862: A randomized controlled trial for irinotecan-eluting beads transarterial chemoembolization with systemic GEMOX (gemcitabine plus oxaliplatin) versus GEMOX in patients with unresectable, local advanced or metastatic intrahepatic cholangiocarcinoma

Not yet recruiting

N/A

150

irinotecan DEB-TACE with GEMOX ;GEMOX treatment

Zhongshan Hospital of Fudan University; Zhongshan Hospital of Fudan University, Fund for Clinical Research, Zhongshan Hospital of Fudan University

intrahepatic cholangiocarcinoma

NCT05247996: TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

Not yet recruiting

N/A

Transcatheter arterial chemoembolization, TACE Thrapy, Multi-target Drug Therapy, Target Therapy, Immunocheckpoint Inhibitor Therapy, Immune Therapy, Systemic Intravenous Chemotherapy, Traditional Chemotherapy

The Central Hospital of Lishui City

Intrahepatic Cholangiocarcinoma

12/22

12/23

ChiCTR2000034829: Camrelizumab Plus Apatinib Versus Chemotherapy for Initial Primary Unresectable Hepatic Carcinoma: a Randomized, Controlled, Single-Center, Phase II Study

Not yet recruiting

N/A

Camrelizumab Plus Apatinib ;Fluorouracil combined with oxaliplatin chemotherapy

Shengjing Hospital Affiliated to China Medical University; Shengjing Hospital Affiliated to China Medical University, Independent project

Hepatic Carcinoma

ChiCTR2000035210: Clinical study on the adjuvant treatment of postoperative cholangjocinoma with duvalizumab combined with GEMOX (gemcitabine+oxaliplatin)

Recruiting

N/A

duvalizumab combined with GEMOX (gemcitabine+oxaliplatin)

Chinese PLA General Hospital (the 301st Hospital); Chinese PLA General Hospital (the 301st Hospital), self-funding

cholangiocarcinoma

NCT05215665: GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

Recruiting

N/A

120

RoW

GEMOX Regimen, Lenvatinib, Toripalimab

Tianjin Medical University Cancer Institute and Hospital

Cholangiocarcinoma

01/24

01/26

NCT06313554: Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Not yet recruiting

N/A

Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin

Fudan University

Intrahepatic Cholangiocarcinoma

05/24

05/27

ChiCTR2100044579: A trial for construction of organoids database and individual drug sensitivity test of patients with cholangiocarcinoma (intrahepatic and extrahepatic cholangiocarcinoma)

Recruiting

N/A

120

Treating with Gemcitabine and Cis-platinum ;Treating with Oxaliplatin and Fluorouracil ;Treating with Gemcitabine and Fluorouracil ;Treating with Gemcitabine ;Treating with Fluorouracil ;Treating with Oxaliplatin

Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Self financing by researchers

cholangiocarcinoma

NCT05932836: An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC

Recruiting

N/A

165

RoW

No interventions.

Xiangya Hospital of Central South University

Hepatocellular Carcinoma

12/25

02/26



	Diseases Companies Products Productz Mechanisms of Action Sites